Eli Lilly's Foundayo Meets Primary Endpoint in Phase 3 Sleep Apnea Trial

11 Of 11 Sectors Rise Monday As Growth Leads

All 11 sectors are higher in Monday’s regular session, with growth sectors holding two of the top three positions. The leaders are separated rather than clustered, with no single gap clearly standing apart from the other breaks across the table.

Why Pfizer Believes It Can Be a Leader in the GLP-1 Market, Even Though Its Drug May Not Debut Until 2028

Pfizer plans to enter the GLP-1 market in 2028 with berobenatide, acquired through its Metsera purchase. Despite a late entry compared to competitors, Pfizer believes its strong commercial execution capabilities, operational scale, and expertise in rapid product rollout (demonstrated with COVID vaccine/pill) position it to become a market leader in the projected $190 billion GLP-1 market by 2035.

FDA Requires Safety Labeling Changes for Glucagon-Like Peptide-1 Receptor Agonists Due to Potential Increased Risk of Rare But Serious Eye Condition

Eli Lilly Gains After Jefferies Raises Price Target to Wall Street-High $1,700

Eli Lilly is rising Monday after Jefferies raised its price target to $1,700, the highest target on Wall Street, according to Investing.com.

Eli Lilly Announces Foundayo Met Primary Endpoint At Week 52 In ATTAIN-OSA Trial To Reduce Apnea-Hypopnea Index; Lowers Sleep Apnea-Specific Hypoxic Burden By Up To An Average Of 55.9%

Eli Lilly Canada Receives Positive Reimbursement Recommendation for Kisunla

Eli Lilly Canada has received a positive reimbursement recommendation from the Canadian Agency for Drugs and Technologies in Health (CDA-AMC) for Kisunla (donanemab) to treat early symptomatic Alzheimer's disease.